Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults - Trial NCT05938946
Access comprehensive clinical trial information for NCT05938946 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pharmosa Biopharm Inc. and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pharmosa Biopharm Inc.
Timeline & Enrollment
Phase 1
Jul 31, 2023
Jun 30, 2024
Primary Outcome
The incidence of dose limiting toxicity (DLT),The incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs),Frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Summary
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose,
 sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses
 of L608 inhalation in healthy volunteers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05938946
Non-Device Trial